Materials and methods relating to modulation of p66 expression
CA 2367464 A1 · Owner: Cancer Research Ventures Limited · Inventors: Lanfrancone, Luisa; Giorgio, Marco; Pelicci, Pier Giuseppe
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
It has been determined that i) p66shc is serine phosphorylated upon UV treatment or oxidative damage; ii) the serine-phosphorylation of p66 by oxidative signals is mediated by Erk1 and p38 as shown both in vivo and in , vitro; iii) ablation of p66shc expression by homologous recombination enhances resistance to oxidative damage both in vitro and in vivo; iv) a serinephosphorylation defective mutant of p66shc is unable to restore a normal stress response in p66shc targeted cells; v) mice carrying the p66shc targeted mutation have prolonged lifespan.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 22, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 22, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 22, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.